• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • HLA Binding Assay
      • Naive CD4+ T Cell Assay
      • Innate Assay
    • Consulting Services
  • About Us
    • Leadership
    • Careers
  • Partner
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Designing a Better Assay – HLA-DR Binding Assays as a Tool for Immunogenicity Screening: Developing the Best Practices for Determining Immunogenicity

Designing a Better Assay – HLA-DR Binding Assays as a Tool for Immunogenicity Screening: Developing the Best Practices for Determining Immunogenicity

by Annie De Groot | Oct 9, 2018

EpiVax_AAPS HLA-binding poster epivax format[1]
Modeling HLA Binding and “Self” Conservation Using In Silico Tools Predicts Immunogenic T Cell Epitopes in Vaccinated Individuals

Modeling HLA Binding and “Self” Conservation Using In Silico Tools Predicts Immunogenic T Cell Epitopes in Vaccinated Individuals

by Annie De Groot | Oct 9, 2018

EpiVax_ISV2018_HLA Binding and Self Conservation_4Oct18
Identification of a Tolerogenic Factor V Peptide and its Potential Role in Factor VIII Tolerance Induction

Identification of a Tolerogenic Factor V Peptide and its Potential Role in Factor VIII Tolerance Induction

by Annie De Groot | Oct 8, 2018

EpiVax_ECI2018_poster_Identification of a Tolerogenic Factor V Peptide_30Aug2018
HLA Binding Assay Design: Impact of HLA binding motif centering on HLA binding results and T cell response; Relevance to Overlapping Peptide Analysis

HLA Binding Assay Design: Impact of HLA binding motif centering on HLA binding results and T cell response; Relevance to Overlapping Peptide Analysis

by Annie De Groot | Oct 5, 2018

Next Entries »

Recent Posts

  • The Platinum Vaccine & Change is Good!
  • EpiVax Appoints Dr. Vibha Jawa to Lead Scientific Strategy as CSO
  • Smarter Tools, Safer Therapies: Supporting the FDA’s Roadmap with in silico Immunogenicity Assessment
  • The Amsterdam Immunogenicity & Tolerance Seminar: 2025
  • The Westin Immunogenicity Seminar

Recent Comments

No comments to show.

Join our newsletter

Stay up to date with EpiVax and greater industry news, events, and technological advancements with this monthly update written by EpiVax co-founder and CMO, Dr. Annie De Groot.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

Partner

News

Events

Publications

Contact Us

We use cookies to ensure that we give you the best experience on our website. By clicking 'accept', you consent to our use of cookies.